Innohep (Tinzaparin Sodium)

Tinzaparin sodium binds to antithrombin III, markedly enhancing its ability to inhibit activated factor Xa and, to a lesser extent, thrombin (factor IIa). By blocking these key enzymes in the coagulation cascade, it reduces fibrin formation and limits clot propagation, providing an anticoagulant effect.

The dose of Innohep is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the amount, frequency, and duration based on the patient’s indication, weight, renal function, and overall risk profile.

The pregnancy category for tinzaparin sodium is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it must be decided by the treating physician.

To order Innohep, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with unfractionated heparin, tinzaparin offers more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring. Relative to other low molecular weight heparins, it has a slightly higher anti‑Xa activity and a lower incidence of heparin‑induced thrombocytopenia, though individual patient factors guide the choice of agent.

Innohep should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Innohep is administered by subcutaneous injection, although it can also be given intravenously in specific clinical situations such as haemodialysis. Injection sites are typically the abdomen or thigh, and the technique should follow aseptic guidelines to minimize local reactions.

The most serious risks associated with Innohep include major bleeding (e.g., gastrointestinal or intracranial hemorrhage), heparin‑induced thrombocytopenia (HIT), and spinal or epidural hematoma, especially after neuraxial procedures. Prompt recognition and medical evaluation are essential if any of these events are suspected.

Innohep is contraindicated in patients with active major bleeding, severe thrombocytopenia (platelet count < 50 × 10⁹/L), known hypersensitivity to tinzaparin or other heparins, and in those with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with uncontrolled hypertension or recent major surgery.